Return to Trial Database

BTCRC-BRE16-042

A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042

Status

Enrollment Closed

Cancer Type(s)

Study Contact

studies@hoosiercancer.org

Trial Locations

All sites in which the trial BTCRC-BRE16-042 being conducted in.

Fred & Pamela Buffett Cancer Center

Michigan State University

New York University Cancer Institute

Rutgers Cancer Institute of New Jersey

University of Wisconsin Carbone Cancer Center